InspireMD, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $42.1M
- Price
- $0.8998
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.01%
- Volume
- 83.9K
About
InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases. The company's offerings, distributed through a network of local partners, reach markets across Europe, Latin America, the Middle East, and Asia Pacific. Key products include the CGuard carotid embolic prevention system, specifically designed for carotid artery procedures, and the MGuard Prime embolic protection systems. The MGuard Prime systems are crucial for patients experiencing acute coronary syndromes, notably acute myocardial infarction, and those undergoing saphenous vein graft coronary interventions or bypass surgery. InspireMD is also developing PVGuard, an innovative solution combining a MicroNet mesh sleeve with a self-expandable stent, aimed at peripheral vascular applications.
Quick stats
Shares outstanding46.8M
Computed float33.6M
Float / shares71.8%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001433607
Websitehttps://www.inspiremd.com
AI Summary
AI-generated1/22
minorneutralearnings
InspireMD Reports Second Quarter 2026 Financial Results
InspireMD reported second quarter revenue of $1.77 million, roughly flat compared to the prior year, as 21% growth in international markets offset the negative impact of a voluntary U.S. product recall.
The company posted a net loss of $14.3 million and announced restructuring measures expected to generate $9 million in annual savings, while also reporting positive 30-day outcomes from its CGUARDIANS II trial.
Cash and cash equivalents fell to $30.4 million from $54.2 million at the end of 2025, reflecting ongoing operating expenses.
Red flags
- Cash position declined from $54.2 million to $30.4 million in six months
- U.S. revenue was negative for the quarter due to recall credits exceeding sales
- Gross loss reported due to inventory impairment and recall charges